Screener
Regeneron Pharmaceuticals REGN Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Regeneron Pharmaceuticals’s reported figures.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
FAQ
- What is Regeneron Pharmaceuticals's enterprise value?
- Regeneron Pharmaceuticals (REGN) reported enterprise value of $65.61B in Q2 2026.
- How has Regeneron Pharmaceuticals's enterprise value changed year-over-year?
- Regeneron Pharmaceuticals's enterprise value increased by 15.0% year-over-year, from $57.08B to $65.61B.
- What is the long-term trend for Regeneron Pharmaceuticals's enterprise value?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's enterprise value has grown at a 9.1% compound annual growth rate (CAGR), from $52.44B to $80.97B.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.
Ask your AI about Regeneron Pharmaceuticals's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude